European Journal of Dermatology
MENUPhototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressivePhototoxicity of B-RAF inhibitors Volume 25, issue 5, September-October 2015
Figures
Clinique Dermatologique,
Hôpital Hôtel-Dieu,
CHU Nantes
Place Alexis Ricordeau,
44093 Cedex 01 - France
Hôpital Hôtel-Dieu,
CHU Nantes
Place Alexis Ricordeau,
44093 Cedex 01 - France
* Reprints
- Key words: B-RAF inhibitors, dabrafenib, melanoma, phototoxicity, vemurafenib, visible light
- DOI : 10.1684/ejd.2015.2628
- Page(s) : 452-6
- Published in: 2015
Metastatic melanoma is an aggressive disease for which few effective treatments existed until 2010 when a radical change in melanoma management occurred. Inhibitory drugs targeting the MAP kinase pathway (B-RAF inhibitors, MEK inhibitors) and immunotherapy (CTLA-4 and PD-1 blockade) revolutionised the therapeutic approach to metastatic melanoma. Among the targeted therapies, vemurafenib (PLX 4032) and dabrafenib (GSK2118436) are inhibitors of B-RAF protein kinase and were developed for patients presenting [...]